{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:55Z","timestamp":1787020855531,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chinese National Major Project for New Drug Innovation","award":["2019ZX09201002003"],"award-info":[{"award-number":["2019ZX09201002003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Despite its inconsistent response rate, decitabine, a demethylating agent, is often used as a non-intensive alternative therapeutic agent for acute myeloid leukemia (AML). It has been reported that relapsed\/refractory AML patients with t(8;21) translocation achieved better clinical outcomes with a decitabine-based combination regimen than other AML subtypes; however, the mechanisms underlying this phenomenon remain unknown. Herein, the DNA methylation landscape of de novo patients with the t(8;21) translocation was compared with that of patients without the translocation. Moreover, the methylation changes induced by decitabine-based combination regimens in de novo\n                      <jats:italic>\/<\/jats:italic>\n                      complete remission paired samples were investigated to elucidate the mechanisms underlying the better responses observed in t(8;21) AML patients treated with decitabine.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty-three bone marrow samples from 28 non-M3 AML patients were subjected to DNA methylation sequencing to identify the differentially methylated regions and genes of interest. TCGA-AML Genome Atlas-AML transcriptome dataset was used to identify decitabine-sensitive genes that were downregulated following exposure to a decitabine-based regimen. In addition, the effect of decitabine-sensitive gene on cell apoptosis was examined in vitro using Kasumi-1 and SKNO-1 cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1377 differentially methylated regions that specifically responsive to decitabine in t(8;21) AML were identified, of which 210 showed hypomethylation patterns following decitabine treatment aligned with the promoter regions of 72 genes. And the methylation-silencing genes,\n                      <jats:italic>LIN7A<\/jats:italic>\n                      ,\n                      <jats:italic>CEBPA<\/jats:italic>\n                      ,\n                      <jats:italic>BASP1<\/jats:italic>\n                      , and\n                      <jats:italic>EMB<\/jats:italic>\n                      were identified as critical decitabine-sensitive genes in t(8;21) AML. Moreover, AML patients with hypermethylated\n                      <jats:italic>LIN7A<\/jats:italic>\n                      and reduced\n                      <jats:italic>LIN7A<\/jats:italic>\n                      expression had poor clinical outcomes. Meanwhile, the downregulation of LIN7A inhibited decitabine\/cytarabine combination treatment-induced apoptosis in t(8;21) AML cells in vitro.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The findings of this study suggest that\n                      <jats:italic>LIN7A<\/jats:italic>\n                      is a decitabine-sensitive gene in t(8;21) AML patients that may serve as a prognostic biomarker for decitabine-based therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13148-023-01458-0","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T22:02:51Z","timestamp":1677794571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["DNA methylation landscape reveals LIN7A as a decitabine-responsive marker in patients with t(8;21) acute myeloid leukemia"],"prefix":"10.1186","volume":"15","author":[{"given":"Shujiao","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanren","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diya","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"issue":"2","key":"1458_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41375-019-0578-6","volume":"34","author":"T Meyer","year":"2020","unstructured":"Meyer T, Jahn N, Lindner S, R\u00f6hner L, Dolnik A, Weber D, et al. Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1). Leukemia. 2020;34(2):404\u201315. https:\/\/doi.org\/10.1038\/s41375-019-0578-6.","journal-title":"Leukemia"},{"issue":"11","key":"1458_CR2","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1345\/aph.1R151","volume":"46","author":"A Ganetsky","year":"2012","unstructured":"Ganetsky A. The role of decitabine for the treatment of acute myeloid leukemia. Ann Pharmacother. 2012;46(11):1511\u20137. https:\/\/doi.org\/10.1345\/aph.1R151.","journal-title":"Ann Pharmacother"},{"issue":"9","key":"1458_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1289524","volume":"58","author":"N Khan","year":"2017","unstructured":"Khan N, Hantel A, Knoebel RW, Artz A, Larson RA, Godley LA, et al. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2017;58(9):1\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1458_CR4","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","volume":"103","author":"JP Issa","year":"2004","unstructured":"Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2\u2032-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103(5):1635\u201340. https:\/\/doi.org\/10.1182\/blood-2003-03-0687.","journal-title":"Blood"},{"issue":"21","key":"1458_CR5","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(21):2670\u20137. https:\/\/doi.org\/10.1200\/JCO.2011.38.9429.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"1458_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.26039","volume":"96","author":"DA Pollyea","year":"2021","unstructured":"Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Am J Hematol. 2021;96(2):208\u201317. https:\/\/doi.org\/10.1002\/ajh.26039.","journal-title":"Am J Hematol"},{"issue":"12","key":"1458_CR7","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","volume":"33","author":"BA Jonas","year":"2019","unstructured":"Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019;33(12):2795\u2013804. https:\/\/doi.org\/10.1038\/s41375-019-0612-8.","journal-title":"Leukemia"},{"issue":"1","key":"1458_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13148-020-00923-4","volume":"12","author":"L Wang","year":"2020","unstructured":"Wang L, Luo J, Chen G, Fang M, Wei X, Li Y, et al. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed\/refractory acute myeloid leukemia: a single-arm, phase 1\/2 study. Clin Epigenetics. 2020;12(1):132. https:\/\/doi.org\/10.1186\/s13148-020-00923-4.","journal-title":"Clin Epigenetics"},{"issue":"3","key":"1458_CR9","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1073\/pnas.1809327116","volume":"116","author":"N Liu","year":"2019","unstructured":"Liu N, Song J, Xie Y, Wang XL, Rong B, Man N, et al. Different roles of E proteins in t(8;21) leukemia: E2\u20132 compromises the function of AETFC and negatively regulates leukemogenesis. Proc Natl Acad Sci USA. 2019;116(3):890\u20139. https:\/\/doi.org\/10.1073\/pnas.1809327116.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1458_CR10","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1038\/s41467-019-12735-z","volume":"10","author":"Y Xu","year":"2019","unstructured":"Xu Y, Man N, Karl D, Martinez C, Liu F, Sun J, et al. TAF1 plays a critical role in AML1-ETO driven leukemogenesis. Nat Commun. 2019;10(1):4925. https:\/\/doi.org\/10.1038\/s41467-019-12735-z.","journal-title":"Nat Commun"},{"issue":"7","key":"1458_CR11","doi-asserted-by":"publisher","first-page":"933","DOI":"10.15252\/emmm.201607180","volume":"9","author":"Y Li","year":"2017","unstructured":"Li Y, Ning Q, Shi J, Chen Y, Jiang M, Gao L, et al. A novel epigenetic AML1-ETO\/THAP10\/miR-383 mini-circuitry contributes to t(8;21) leukaemogenesis. EMBO Mol Med. 2017;9(7):933\u201349. https:\/\/doi.org\/10.15252\/emmm.201607180.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"1458_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","volume":"17","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17(1):13\u201327. https:\/\/doi.org\/10.1016\/j.ccr.2009.11.020.","journal-title":"Cancer Cell"},{"issue":"66","key":"1458_CR13","doi-asserted-by":"publisher","first-page":"110444","DOI":"10.18632\/oncotarget.22789","volume":"8","author":"Y Li","year":"2017","unstructured":"Li Y, Zhao H, Xu Q, Lv N, Jing Y, Wang L, et al. Detection of prognostic methylation markers by methylC-capture sequencing in acute myeloid leukemia. Oncotarget. 2017;8(66):110444\u201359. https:\/\/doi.org\/10.18632\/oncotarget.22789.","journal-title":"Oncotarget"},{"issue":"6","key":"1458_CR14","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1093\/nar\/gkt1325","volume":"42","author":"G Kunde-Ramamoorthy","year":"2014","unstructured":"Kunde-Ramamoorthy G, Coarfa C, Laritsky E, Kessler NJ, Harris RA, Xu M, et al. Comparison and quantitative verification of mapping algorithms for whole-genome bisulfite sequencing. Nucleic Acids Res. 2014;42(6):e43. https:\/\/doi.org\/10.1093\/nar\/gkt1325.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"1458_CR15","first-page":"841","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinform (Oxford, England). 2010;26(6):841\u20132.","journal-title":"Bioinform (Oxford, England)"},{"issue":"16","key":"1458_CR16","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/bioinformatics\/btq033","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164. https:\/\/doi.org\/10.1093\/bioinformatics\/btq033.","journal-title":"Nucleic Acids Res"},{"issue":"23","key":"1458_CR17","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1042\/CS20200786","volume":"134","author":"E Yang","year":"2020","unstructured":"Yang E, Guan W, Gong D, Gao X, Han C, Zhang J, et al. Epigenetic silencing of miR564 contributes to the leukemogenesis of t(8;21) acute myeloid leukemia. Clin Sci (London, England: 1979). 2020;134(23):3079\u201391. https:\/\/doi.org\/10.1042\/CS20200786.","journal-title":"Clin Sci (London, England: 1979)"},{"issue":"10","key":"1458_CR18","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s43018-021-00249-x","volume":"2","author":"MB Pappalardi","year":"2021","unstructured":"Pappalardi MB, Keenan K, Cockerill M, Kellner WA, Stowell A, Sherk C, et al. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nature cancer. 2021;2(10):1002\u201317.","journal-title":"Nature cancer"},{"issue":"14","key":"1458_CR19","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-06-2762","volume":"13","author":"T Qin","year":"2007","unstructured":"Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, Garcia-Manero G, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res. 2007;13(14):4225\u201332. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2762.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"1458_CR20","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1200\/JCO.2006.09.4169","volume":"25","author":"W Blum","year":"2007","unstructured":"Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(25):3884\u201391. https:\/\/doi.org\/10.1200\/JCO.2006.09.4169.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"1458_CR21","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1182\/blood.V100.8.2957","volume":"100","author":"M Daskalakis","year":"2002","unstructured":"Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, K\u00f6hler G, Wijermans P, et al. Demethylation of a hypermethylated P15\/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2\u2032-deoxycytidine (decitabine) treatment. Blood. 2002;100(8):2957\u201364. https:\/\/doi.org\/10.1182\/blood.V100.8.2957.","journal-title":"Blood"},{"issue":"4","key":"1458_CR22","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1158\/0008-5472.CAN-04-4532","volume":"65","author":"S Liu","year":"2005","unstructured":"Liu S, Shen T, Huynh L, Klisovic MI, Rush LJ, Ford JL, et al. Interplay of RUNX1\/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Can Res. 2005;65(4):1277\u201384. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-4532.","journal-title":"Can Res"},{"issue":"4","key":"1458_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s12276-018-0067-4","volume":"50","author":"L Zhou","year":"2018","unstructured":"Zhou L, Fu L, Lv N, Liu J, Li Y, Chen X, et al. Methylation-associated silencing of BASP1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia. Exp Mol Med. 2018;50(4):44. https:\/\/doi.org\/10.1038\/s12276-018-0067-4.","journal-title":"Exp Mol Med"},{"issue":"4","key":"1458_CR24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ccr.2014.07.028","volume":"26","author":"X Yang","year":"2014","unstructured":"Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell. 2014;26(4):577\u201390. https:\/\/doi.org\/10.1016\/j.ccr.2014.07.028.","journal-title":"Cancer Cell"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-023-01458-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-023-01458-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-023-01458-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T22:02:57Z","timestamp":1677794577000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-023-01458-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1458"],"URL":"https:\/\/doi.org\/10.1186\/s13148-023-01458-0","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]},"assertion":[{"value":"3 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol for the use of clinical samples was approved by the Ethics Committee of the Chinese People's Liberation Army General Hospital and conducted in accordance with the principles of the Helsinki Declaration. Written informed consent was obtained from all participants prior to specimen collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}